Linkedin Twitter
Small Molecules that
Modify RNA Expression
At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that modify RNA expression, targeting some of the world's most intractable diseases
LEARN MORE
The Science of Skyhawk
SkySTAR Skyhawk Small molecule Therapeutics for Alternative modulation of RNA
LEARN MORE
Skyhawk News
Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic...
READ ARTICLE
Our Mission
Our mission is to revolutionize disease treatment by developing small molecule therapeutics that modify RNA expression
LEARN MORE
Previous
Next

OUR PARTNERS

Skyhawk News

The latest news, videos and press from Skyhawk Therapeutics, our groundbreaking partners and the science behind what we do. 

Drugging RNA with pills: small molecules for a big frontier

READ MORE >

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

READ MORE >

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

READ MORE >

Bill Haney's latest startup scores deal from Sanofi, its newest Big Pharma partner, with $54M upfront

READ MORE >

Skyhawk Therapeutics Completes New Investment Round

READ MORE >

ALL NEWS

WHAT WE DO

ONCOLOGY

NEUROLOGY

INFLAMMATORY INFECTIOUS RARE

NEUROMUSCULAR & METABOLIC
LEARN MORE

Skyhawk Therapeutics, Inc.
35 Gatehouse Drive
Waltham, MA 02451
United States of America

[email protected]
617.858.0041

Skyhawk Therapeutics
Europe GmbH
Basel Technology Park
Hochbergerstrasse 60C
Basel 4057 Switzerland

[email protected]
+41 (0) 61 638 23 50

Scroll to Top